NRXS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Neuraxis Inc (NRXS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows bullish technical indicators, a positive analyst rating with an increased price target, and a significant growth catalyst from expanded national coverage. While financials show losses, revenue growth and improved net income trends suggest potential for long-term growth.
The technical indicators for NRXS are bullish. The MACD histogram is positive and expanding, the RSI is neutral at 69.655, and the moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). The pre-market price of $5.74 is near the first resistance level (R1: 5.724), indicating potential upward momentum.
Craig-Hallum raised the price target to $8 from $7 and maintained a Buy rating.
Expanded national coverage for IBStim, adding 45M lives and unlocking significant pediatric market opportunities.
Revenue increased by 21.72% YoY in Q3 2025, showing strong growth potential.
The company is still operating at a net loss (-$2,321,503 in Q3 2025).
EPS dropped by 4.00% YoY, and gross margin declined slightly by 2.50%.
In Q3 2025, revenue increased by 21.72% YoY to $811,414, and net income improved by 28.97% YoY to -$2,321,503. However, EPS dropped by 4.00% YoY to -0.24, and gross margin declined slightly to 83.3%.
Craig-Hallum raised the price target to $8 from $7 and maintained a Buy rating, citing expanded national coverage for IBStim and significant market opportunity in the pediatric segment.
